论文部分内容阅读
目的探讨卡培他滨(希罗达)单药治疗老年晚期胃肠癌的近期疗效及不良反应。方法对32例老年晚期胃肠癌患者采用希罗达1250mg/m2,口服,2次/天,d1～d14,21天为一周期,至少使用2周期,结束后进行疗效及不良反应评价。结果 32例中CR0例,PR9例,SD15例,PD8例,RR为28.1%,受益率为75.0%,不良反应多为Ⅰ～Ⅱ度,患者均可耐受。结论希罗达单药治疗老年晚期胃肠癌疗效肯定,不良反应轻微,值得临床推广使用。
Objective To investigate the short-term efficacy and side effects of capecitabine (Xeloda) monotherapy in the treatment of elderly patients with advanced gastrointestinal cancer. Methods Thirty-two elderly patients with advanced gastrointestinal cancer were treated with Xeloda 1250mg / m2, orally, twice daily, d1 ~ d14 for 21 days for at least two cycles. Efficacy and side effects were evaluated after the treatment. Results Of the 32 patients, CR0, PR9, SD15 and PD8 had a RR of 28.1% and a benefit rate of 75.0%. Adverse reactions were mostly grade Ⅰ ~ Ⅱ, and patients were tolerant. Conclusion Xeloda monotherapy for the treatment of elderly patients with advanced gastrointestinal cancer is positive, minor adverse reactions, it is worth to promote the use of the clinic.